Merge PACS
Merge Healthcare Incorporated • Radiology • 10/17/2019
Device Purpose
Merge PACS is an advanced software-based Picture Archiving and Communication System designed to streamline medical imaging workflows by enabling multi-modality image viewing, processing, reporting, and storage, utilizing DICOM and HL7 standards for interoperability. This version introduces enhanced clinical analysis capabilities, most notably volumetric Standard Uptake Value (SUV) calculations and Region Analysis tools, to support more detailed diagnostic assessment, particularly in PET imaging.
Summary
Merge PACS is a software-based Picture Archiving and Communication System (PACS) designed for multi-modality medical image processing, display, diagnostic reading, reporting, communication, printing, and storage. It supports a wide range of imaging modalities (CT, MR, PET, US, MG, BTO, CR, DR/DX, NM, XA, RF, SC, etc.) and is intended for use by radiologists, orthopedic and other surgeons, referring physicians, technologists, and other qualified medical professionals. The system can receive data directly from acquisition devices or via import, converting non-DICOM data like photos into DICOM format. It integrates with hospital information systems (HIS/RIS) via HL7 and vendor-neutral archives (VNAs) via DICOM, running on standard computer hardware with local or remote web-based access, though mobile device viewing is not intended for diagnostic purposes. Merge PACS provides clinicians with a suite of tools for image manipulation, including linking, Multi-Planar Reconstruction (MPR), Maximum Intensity Projection (MIP), 3D image fusion/registration (CT, MR, and PET), Color Volume Rendering (CVR), various measurements (linear distances, angles, areas, SUV, etc.), and annotations. A significant enhancement in this version is the addition of Region Analysis Area and Region Analysis Volume tools, which enable more advanced clinical analysis of images, particularly volumetric Standard Uptake Value (SUV) calculation for PET images, an advancement from previous 2D SUV capabilities. The system also features a Real Time Worklist (RTWL) for workflow management, a Patient Dashboard for a composite view of patient data, and supports both lossless and lossy image compression, with specific guidelines for mammography image interpretation, stipulating that lossy compressed or digitized screen film mammography images are not for primary diagnosis.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the new volumetric SUV calculation compare to established methods in terms of accuracy and processing time, particularly across different PET scanner models and reconstruction algorithms?; What specific validation studies were conducted to ensure the accuracy and reliability of the 3D image fusion/registration tools, especially when combining images from different modalities like CT, MR, and PET?; Can the Region Analysis Area and Volume tools be customized or adapted for specific anatomical regions or pathological conditions beyond general PET image analysis?; What are the quantitative benefits (e.g., time savings, diagnostic accuracy improvements) observed with the enhanced Real Time Worklist and Patient Dashboard features in a clinical setting?; Considering the system integrates with various HIS/RIS and VNAs, what are the data security and interoperability safeguards in place, especially for remote web-based access and multi-tier patient identity matching?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly